Xilio Therapeutics, Inc. XLO
We are a clinical-stage biotechnology company discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer. Leveraging our clinically-validated masking technology and capabilities, we are developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Our integrated biology and protein engineering approach enables us to design and develop highly potent, masked biologics that are activated, or unmasked, by tumor-specific proteases within the tumor microenvironment. We are currently advancing multiple programs in preclinical and clinical development, including masked multi-specifics, and our clinically-validated masking technology has enabled us to establish top-tier strategic partnerships, including with AbbVie Group Holdings Limited, or AbbVie, and Gilead Sciences, Inc., or Gilead.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | — | — | — | — | — |
| R&D | $56.0M | $41.2M | $52.1M | $59.2M | $51.2M | $43.9M | — |
| SG&A | $29.7M | $24.8M | $27.0M | $29.9M | $23.9M | $10.7M | — |
| Total operating expenses | $85.7M | $66.9M | $79.1M | $89.1M | $75.0M | $54.6M | — |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M | -$54.6M | — |
| Pre-tax income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M | -$55.2M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M | -$55.2M | — |
| EPS, basic | -4.19 | -15.24 | -2.78 | -3.22 | -13.52 | -105.42 | — |
| EPS, diluted | -4.19 | -15.24 | -2.78 | -3.22 | -13.52 | -105.42 | — |
| Shares, diluted (wtd. avg.) | 8.4M | 3.8M | 27.5M | 27.4M | 5.6M | 523,786 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $137.5M | $55.3M | $46.3M | $121.9M | $199.6M | $20.8M | $49.0M |
| Total current assets | $145.0M | $60.2M | $48.1M | $124.5M | $202.5M | $20.6M | — |
| Property, plant and equipment | $3.9M | $4.5M | $5.9M | $7.3M | $7.6M | $7.4M | — |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M | $36.3M | — |
| Accounts payable | $3.2M | $2.6M | $1.1M | $3.1M | $3.1M | $5.4M | — |
| Total current liabilities | $56.3M | $27.3M | $16.0M | $21.1M | $12.8M | $22.2M | — |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M | $41.6M | — |
| Retained earnings | -$418.8M | -$383.8M | -$325.5M | -$249.1M | -$160.9M | -$85.1M | — |
| Total equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M | -$83.3M | -$29.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M | -$36.1M | — |
| Depreciation and amortisation | $1.5M | $1.6M | $1.9M | $1.8M | $1.5M | $1.1M | — |
| Stock-based compensation | $6.9M | $6.4M | $7.4M | $8.4M | $5.0M | $1.3M | — |
| Capital expenditure | $518.0K | $36.0K | $486.0K | $1.9M | $1.1M | $2.2M | — |
| Investing cash flow | -$518.0K | -$36.0K | -$486.0K | -$1.9M | -$1.1M | -$2.2M | — |
| Financing cash flow | $87.8M | $29.2M | -$6.5M | -$69.0K | $260.7M | $10.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-118550.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $6.3M | $43.8M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$55.2M | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |